Trials / Completed
CompletedNCT04756921
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Pretreatment 18F-FDG Uptake Heterogeneity Predicts Response to Pyrotinib in Patients With Metastatic HER2-positive Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Biyun Wang, MD · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- —
Summary
Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/computed tomography (PET/CT) 18F-FDG-based heterogeneity to predict the response to pyrotinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyrotinib | Pyrotinib 400mg po qd |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2020-07-24
- Completion
- 2020-07-24
- First posted
- 2021-02-16
- Last updated
- 2021-02-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04756921. Inclusion in this directory is not an endorsement.